Auch auf Deutsch: Lipoprotein(a): der vererbte Risikofaktor.
Lipoprotein(a), written Lp(a), is an LDL-like particle with an additional protein, apolipoprotein(a), attached. According to the 2022 European Atherosclerosis Society (EAS) consensus statement, there is strong evidence of a causal, continuous association between Lp(a) concentration and cardiovascular outcomes, including aortic valve stenosis, and elevated Lp(a) is a risk factor even when LDL cholesterol is very low.
Mostly inherited
The EAS reports that Lp(a) concentration is more than 90% determined by genetic variation at the LPA gene. Levels reach adult values by around age 20, and lifestyle has little effect on them. That is why a single measurement is informative.
Measure it once
The EAS panel recommends measuring Lp(a) at least once in every adult, and suggests cascade testing in families with familial hypercholesterolaemia or a personal or family history of very high Lp(a) or premature cardiovascular disease. Commonly used risk bands from the consensus summary are below 30 mg/dL (below 75 nmol/L) for lower risk, 30 to 50 mg/dL (75 to 125 nmol/L) intermediate, and above 50 mg/dL (above 125 nmol/L) higher risk. Around 20% of the global population has elevated levels.
What to do with a high result
There is no approved therapy that specifically lowers Lp(a) yet; specific drugs are being tested in trials. The EAS recommends early, intensive management of the other risk factors, guided by your overall cardiovascular risk and your Lp(a) level. Discuss a high result with your physician. Lp(a) fits alongside ApoB and LDL cholesterol in a full cardiovascular picture.
Aeonix includes Lp(a) in every plan. See plans and prices.
Frequently asked questions
How often should Lp(a) be tested?
The 2022 EAS consensus recommends measuring Lp(a) at least once in adulthood, because levels are largely genetically determined and stable.
Can diet or exercise lower Lp(a)?
Lp(a) is more than 90% genetically determined and responds little to lifestyle. Managing other risk factors remains important.
Sources
- Kronenberg F et al. Lipoprotein(a) in ASCVD and aortic stenosis: EAS consensus statement. Eur Heart J 2022
- American College of Cardiology: Key points, EAS Lp(a) consensus 2022
- Novartis Pro: Lp(a) key insights from the 2022 consensus statement
Aeonix: Own Your Health
Up to 150+ clinically validated biomarkers. Physician-reviewed results in 48–72 hours. Renowned Swiss lab. GDPR-compliant.
Join Waitlist Now